How Long Does Retatrutide Last in the Fridge? Beyond-Use Date Logic

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited

Key Takeaways

• Retatrutide is investigational and not FDA-approved. FormBlends does not supply retatrutide. Direct stability data are not yet published; the discussion here draws on analogous approved peptides and USP 797 standards
• Reconstituted peptide at 2-8 C typically retains potency for 14 to 28 days based on data from structurally similar approved peptides (semaglutide, tirzepatide)
• Beyond-use dates (BUDs) are set by USP 797: 14 days baseline for low-risk refrigerated compounded sterile preparations, extendable with documented stability data
• Lyophilized starting material (unmixed) stores far longer at refrigeration, typically through the manufacturer's expiration
• Practical fridge storage is straightforward, but small habits (door storage, freezer adjacency, hot leftovers placed nearby) can push temperature outside the 2-8 C window

Direct answer

The honest answer for retatrutide specifically is that published stability data are not yet available, because the product is investigational. By analogy with semaglutide and tirzepatide (both structurally similar and both with extensive stability data), reconstituted peptide stored at 2-8 degrees Celsius typically retains potency for 14 to 28 days. Compounding pharmacies in the U.S. work within USP 797 beyond-use date categories: 14 days baseline for low-risk refrigerated compounded sterile preparations, extendable to 28 days with documented peptide-specific stability work. Lyophilized starting material (before reconstitution) stores much longer. FormBlends does not supply retatrutide; this is educational, not a guide for personal preparation.

Table of contents

1. The difference between expiration and beyond-use date
2. Lyophilized vs reconstituted: two different timelines
3. What USP 797 actually requires
4. What stability data on similar peptides show
5. What can shorten the practical shelf life
6. What can extend the BUD legitimately
7. Real-world fridge problems
8. What the trial pharmacies do
9. The decision framework for understanding your dispensing label
10. FAQ
11. Sources

The difference between expiration and beyond-use date

Two date concepts often get conflated:

Expiration date is set by the manufacturer of the starting material. It is based on stability testing under defined storage conditions (typically refrigerated for peptide products). For a lyophilized peptide, the expiration date is often two years from manufacture. The expiration applies to the unmixed product in its sealed vial.

Beyond-use date (BUD) is set by the compounding pharmacist for the reconstituted preparation. The BUD is much shorter than the expiration because reconstitution introduces water, which accelerates degradation, and because the multi-dose vial gets punctured weekly, which introduces contamination risk.

For retatrutide research material (which is not legally available as a prescription compounded product in the U.S.), neither date is straightforward. The "expiration" on research material labeling is not subject to the same regulatory verification as a prescription product. The BUD does not apply because the material is not legally compounded.

For approved peptide analogs (semaglutide, tirzepatide), both dates appear on the label, and both follow the standard manufacturing and compounding frameworks.

Lyophilized vs reconstituted: two different timelines

The single most important storage distinction is whether the vial has been reconstituted.

Form	Typical refrigerated stability	Limiting factor
Lyophilized (dry cake)	Months to years (through manufacturer expiration)	Long-term chemical degradation; container integrity
Reconstituted with BWFI	14-28 days (USP 797 low-risk category)	Aqueous-phase degradation; cumulative puncture contamination
Reconstituted with SWFI (no preservative)	Hours to days; single-use preferred	Microbial contamination risk without preservative
Reconstituted, room temperature	Days at most	Accelerated chemical and physical degradation

The dramatic difference between lyophilized and reconstituted stability is why pharmacies reconstitute close to the dispensing event rather than mixing entire batches at once. Each reconstituted vial has a fresh, individualized BUD.

What USP 797 actually requires

United States Pharmacopeia General Chapter 797 sets default BUDs for compounded sterile preparations by risk category and storage condition. The relevant numbers:

• Low-risk CSP, controlled room temperature (20-25 C): 48 hours
• Low-risk CSP, refrigerated (2-8 C): 14 days
• Low-risk CSP, frozen (-20 C): 45 days
• Medium-risk CSP, refrigerated: 9 days
• High-risk CSP, refrigerated: 3 days

Low-risk applies to simple reconstitution of a lyophilized peptide inside an ISO Class 5 hood. Most pharmacy-compounded peptide preparations fall into the low-risk, refrigerated category.

Pharmacies can extend BUDs only with documented peptide-specific stability data. The data must come from stability-indicating analytical methods (typically HPLC with peptide-specific detection) showing potency retention through the proposed BUD. This is a real investment for the pharmacy, not a paperwork exercise.

The 28-day BUD that some compounding pharmacies use for semaglutide and tirzepatide reflects exactly this kind of in-house stability work. For retatrutide, equivalent data are not yet available in the public domain.

What stability data on similar peptides show

Although retatrutide-specific data are not yet published, related peptides provide useful reference points:

Semaglutide: Multiple published stability studies on compounded semaglutide preparations at 2-8 C show greater than 95% potency retention through 28 days, and greater than 90% retention through 42 days in some formulations. Manufacturer-prepared semaglutide injectable (Ozempic, Wegovy) carries a shorter in-use BUD per the FDA label (56 days for Ozempic pen after first use, refrigerated).

Tirzepatide: Compounded tirzepatide stability data show similar profiles. Manufacturer-prepared tirzepatide (Mounjaro, Zepbound) is supplied in single-use prefilled pens with manufacturer-controlled storage windows.

Liraglutide: An earlier GLP-1 with extensive stability data, used as a comparator. Reconstituted liraglutide is stable for similar windows under refrigeration.

Retatrutide shares the basic peptide architecture (~39 amino acids, fatty acid acylation for half-life extension) with these peptides. The reasonable expectation is similar stability behavior. The reasonable caveat is that "expected" is not the same as "measured."

What can shorten the practical shelf life

Even within a legitimately set 14- or 28-day BUD, several things can shorten the practical usable life:

• Temperature excursions. Each significant exposure outside 2-8 C accelerates cumulative degradation. A vial that sits on a counter for several hours before being returned to the fridge has lost some of its stability budget
• Sub-zero exposure. Freezing or near-freezing temperatures can damage peptide structure. A vial placed too close to the freezer compartment or against a cold spot at the back of the fridge can be partially compromised even if the visible solution looks intact
• Light exposure. Direct sunlight, prolonged exposure to bright indoor light, or storage in clear containers near a window can accelerate photo-oxidation
• Multiple septum punctures with imperfect technique. Each puncture is a potential contamination event. With pristine technique and BWFI as the diluent, contamination risk stays low through the BUD. With sloppy technique, microbial growth can begin earlier
• Shipping mishaps before pharmacy receipt. Although this is upstream of the patient, it affects the starting material's remaining stability

The patient cannot quantify any of these from visual inspection. The conservative pharmacy approach is to assume worst case and set the BUD with margin.

What can extend the BUD legitimately

Only one thing legitimately extends the BUD: documented stability-indicating data on the specific formulation, prepared by the specific pharmacy, stored under the specific conditions claimed.

The required data typically include:

• Stability-indicating HPLC assay for potency retention
• Aggregate quantification (size exclusion chromatography or similar)
• Sterility testing at the BUD endpoint
• Visual inspection at intervals through the proposed BUD
• pH and appearance monitoring

This is real laboratory work. The pharmacies that have invested in this work for semaglutide and tirzepatide can defend their extended BUDs with the supporting data. Pharmacies that simply claim extended BUDs without data are not following USP 797.

For retatrutide specifically, the legal-compounding question (retatrutide is not on FDA's bulk substances list approved for 503A compounding) precedes the BUD question. A pharmacy that is not legally compounding retatrutide does not have a legitimate path to set or extend a BUD on it.

Real-world fridge problems

Patient questions about fridge storage usually involve concrete situations. A few common ones:

The fridge was opened repeatedly during a long power outage. If the fridge was closed and unopened for the duration, contents typically stay cold for several hours. If the fridge was opened frequently or the outage was long enough to reach near room temperature, ask the dispensing pharmacist whether to discard the affected vials.

The vial was left in a hot car. A car interior in summer can exceed 50 C. Sustained exposure at those temperatures meaningfully degrades peptides. The conservative call is to discard.

The vial accidentally touched the back wall of the fridge and froze. If the contents are frozen, they should not be used after thawing. Ice crystal damage to peptide structure is not reversible.

The fridge thermostat drifted, and the temperature ran around 12 C for a week. Sustained exposure above the 2-8 C range progressively reduces potency. The dispensing pharmacy can offer guidance on whether the affected vials should be discarded.

The vial was stored next to a soup container that came out of the microwave at 70 C. Brief proximity to a hot container can temporarily raise the local temperature around the vial. Repeated incidents add up.

What the trial pharmacies do

In the Phase 2 retatrutide trial (Jastreboff et al., New England Journal of Medicine 2023), trial site pharmacies stored sponsor-supplied product under Good Clinical Practice rules: monitored refrigeration, documented temperature logs, access logging, and chain-of-custody records.

Patients received product in dispensing containers with explicit storage instructions: refrigerated 2-8 C, away from light, do not freeze, return unused product at study close. Temperature excursions during patient possession were documented; sustained excursions could trigger replacement of the affected dose.

The fridge-storage discipline in the trial context is essentially the same as the compounded-pharmacy discipline, with more documentation. The science doesn't care which framework the patient is operating in; it cares about temperature, light, and time.

The decision framework for understanding your dispensing label

If you have a labeled vial of a compounded peptide (semaglutide or tirzepatide, since retatrutide is not legally dispensed for outpatient use):

Check three things on the label:

• Beyond-use date. This is your "do not use after" date
• Storage condition (almost always "refrigerate, do not freeze, protect from light")
• Concentration and dose volume per administration

Two things to remember about the BUD:

• It assumes the vial was stored properly the entire time. Significant temperature excursions invalidate the BUD even if calendar time hasn't expired
• It is conservative. Some potency likely remains a few days past the BUD, but the safety margin shrinks. The pharmacy chose the date deliberately

For retatrutide specifically:

• The product is investigational. Clinical trial enrollment is the only legitimate pathway for receiving it under medical supervision in the U.S. as of May 2026
• FormBlends does not supply retatrutide

FAQ

How long does retatrutide last in the fridge? Direct data are not yet published because the product is investigational. By analogy with semaglutide and tirzepatide, reconstituted peptide at 2-8 C typically retains potency for 14 to 28 days. Lyophilized starting material lasts much longer. FormBlends does not supply retatrutide.

What is a beyond-use date? The date after which a compounded preparation should not be administered. USP 797 sets defaults by risk category and storage condition: 14 days baseline for low-risk refrigerated CSPs.

Can a 28-day BUD be assigned? With documented peptide-specific stability data, yes. Pharmacies that have invested in stability-indicating assay work can justify extended BUDs. Without that data, the 14-day default applies.

What happens if I use retatrutide past its BUD? Potency declines past the BUD. Clinical effect may be reduced. Beyond significant degradation thresholds, aggregation and breakdown products may also pose safety concerns. Not recommended.

Does the BUD reset when I open a new vial? Each new vial has its own BUD starting from its reconstitution date. A fresh vial does not extend the BUD on an older vial.

What if I forget to refrigerate retatrutide for a few hours? Brief excursions are generally tolerated. Sustained room-temperature exposure reduces potency. Document and ask the dispensing pharmacist for guidance.

Can I store retatrutide in a cooler with ice during travel? Yes, with care. Direct ice contact can drop the vial below 2 C and freeze the contents. Gel packs at refrigerated temperature are safer. Validated medical travel coolers are designed for this purpose.

Why do pharmacies use 14-28 day BUDs and not longer? USP 797 sets 14 days as the default low-risk refrigerated BUD. Extensions require documented stability data. Even with data, longer windows are rare because cumulative contamination risk and visual deterioration also limit practical use.

What does a degraded peptide solution look like? Cloudiness, color change, or visible particulates are clear rejection signs. Subtle degradation may not be visually detectable; this is why conservative BUDs and proper storage matter rather than relying on visual inspection.

Should I keep a fridge thermometer to monitor temperature? For patients managing injectable medication that requires refrigeration, a basic fridge thermometer is a low-cost way to verify the 2-8 C range. Fridge thermostat dials are notoriously inaccurate.

Related guides

• Is Retatrutide Safe for Long-Term Use?
• Is Retatrutide Safe for Long Term Use?
• Where to Buy Retatrutide in 2026: What "For Research Use Only" Really Means
• Retatrutide Alternatives: What to Use While Waiting
• Retatrutide Compassionate Use Program Access
• How Long Does Reconstituted 10 mg Retatrutide Stay Stable?

Sources

1. Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526.
2. United States Pharmacopeia. General Chapter <797> Pharmaceutical Compounding: Sterile Preparations. 2023 revision.
3. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of Protein Pharmaceuticals: An Update. Pharmaceutical Research. 2010;27(4):544-575.
4. FDA Prescribing Information: Ozempic (semaglutide injection). Novo Nordisk. Updated 2024.
5. FDA Prescribing Information: Wegovy (semaglutide injection). Novo Nordisk. Updated 2024.
6. FDA Prescribing Information: Mounjaro (tirzepatide injection). Eli Lilly. Updated 2024.
7. FDA Prescribing Information: Zepbound (tirzepatide injection). Eli Lilly. Updated 2024.
8. American Society of Health-System Pharmacists. ASHP Guidelines on Compounding Sterile Preparations. 2023.
9. International Council for Harmonisation. ICH Q1A(R2): Stability Testing of New Drug Substances and Products.
10. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
11. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends operates a digital health platform connecting patients to U.S.-licensed providers and state-licensed pharmacies. We do not manufacture, prescribe, or dispense medication. We do not sell or supply retatrutide. All clinical decisions belong to the patient and an independent licensed prescriber.

Compounded Medication Notice. Compounded medications from state-licensed 503A pharmacies follow USP 797 standards but are not FDA-approved and have not undergone the agency review applied to brand-name drugs. They are not interchangeable with FDA-approved products.

Results Disclaimer. Beyond-use date and stability information here is drawn from peptide chemistry literature, USP 797 framework, and analogous approved peptides. Direct stability data on retatrutide are not yet published. This material is educational, not a guide for personal preparation.

Trademark Notice. Retatrutide is the developmental designation for an investigational compound from Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends has no affiliation or endorsement with the named companies or institutions.